Hyperkalemia in type 2 diabetes occurred less often with GLP-1 receptor agonists in routine care than dipeptidyl peptidase-4 ...

MONDAY, Aug. 12, 2024 (HealthDay News) -- Treatment with glucagon-like peptide 1 receptor agonists (GLP-1 RAs) is associated with lower rates of hyperkalemia ... with type 2 diabetes (T2D ...

Risk factors for developing hyperkalemia include renal insufficiency, diabetes mellitus, advanced heart failure, advanced age, and concurrent drug therapy. Svensson et al. [72] identified 125 ...

In addition to improving heart failure symptoms, finerenone reduced the onset of new type 2 diabetes in patients with mildly ...

Two classes of newer medications for glycemic control in type 2 diabetes differed in hyperkalemia risk and discontinuation of renin-angiotensin system inhibitors, a large cohort study found. In ...

A medication that is currently used for chronic kidney disease in patients with type 2 diabetes has been found to reduce the ...

Journal of diabetes science and technology ... People with chronic kidney disease (CKD) are at increased risk of hyperkalemia, an electrolyte abnormality that can cause serious, sometimes fatal, ...

is associated with lower rates of hyperkalemia and a lower rate of renin-angiotensin system inhibitor (RASi) discontinuation compared with treatment with dipeptidyl peptidase-4 inhibitors (DPP-4is) ...

THESE WERE ALL PATIENTS WITH TYPE TWO DIABETES OKAY. AND CHRONIC KIDNEY ... that people taking finerenone showed a higher risk of hyperkalemia, or having too much potassium in the blood.